Skip to main content

Table 1 Baseline demographic and clinicopathologic features of the mammary NEC cohort and the invasive mammary carcinoma control cohort from the SEER database (2003–2009)

From: Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database

Characteristics NEC   Invasive mammary carcinoma   P
Age, years, mean ± SD 63.6 ± 14.9 61.3 ± 14.2 0.029
Tumor size (mm), mean ± SD 31.9 ± 31.1 22.5 ± 24.1 <0.0001
  No. of patients % No. of patients %  
Sex      0.06a
 Male 3 2.1 2,909 0.8  
 Female 139 97.9 378,735 99.2  
Race      NS
 White 121 85.2 312,513 81.9  
 Black 13 9.2 38,975 10.2  
 Other 8 5.6 30,156 7.9  
AJCC TNM stage      <0.0001*
 I 32 22.5 173,349 45.4  
 II 52 36.6 125,129 32.8  
 III 16 11.3 42,020 11.0  
 IV 34 23.9 18,844 4.9  
 Unknown 8 5.6 22,302 5.8  
Regional lymph node      0.05*
 Negative 52 36.6 214,745 56.3  
 Positive 40 28.2 109,741 28.8  
 Unknown 50 35.2 57,158 14.9  
Grade      <0.0001*
 I 17 12.0 75,043 19.7  
 II 30 21.1 147,540 38.7  
 III 60 42.3 126,919 33.3  
 Unknown 35 24.7 32,142 8.3  
ER status      0.003**
 Negative 37 26.1 74,093 19.4  
 Borderline 0 0 812 0.2  
 Positive 77 54.2 274,474 71.9  
 Unknown 28 19.7 32,265 8.5  
PR status      <0.0001**
 Negative 59 41.6 114,069 29.9  
 Borderline 0 0 2,626 0.7  
 Positive 53 37.3 228,877 60.0  
 Unknown 30 21.1 36,214 9.5  
Surgery      <.0001*
 No 33 23.2 28,888 7.6  
 Yes 109 76.8 352,865 92.4  
Radiation      0.038
 No 91 64.1 211,458 55.4  
 Yes 51 35.9 170,186 44.6  
  1. NEC, neuroendocrine carcinoma; TNM, tumor-lymph nodes-metastasis; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor; NS, not significant.
  2. aFisher exact test.
  3. *Cases with other or unknown status were excluded from statistical analysis.
  4. **Cases with borderline or unknown status were excluded from statistical analysis.